S
Stacie A. Dalrymple
Researcher at Celera Corporation
Publications - 9
Citations - 976
Stacie A. Dalrymple is an academic researcher from Celera Corporation. The author has contributed to research in topics: In vivo & Acetylation. The author has an hindex of 6, co-authored 9 publications receiving 882 citations.
Papers
More filters
Journal ArticleDOI
Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase
Zhengying Pan,Heleen Scheerens,Shyr-Jiann Li,Brian E. Schultz,Paul A. Sprengeler,L. Chuck Burrill,Rohan Mendonca,Michael D. Sweeney,Keana C. Scott,Paul G. Grothaus,Douglas A. Jeffery,Jill M. Spoerke,Lee Honigberg,Peter R. Young,Stacie A. Dalrymple,James T. Palmer +15 more
TL;DR: The discovery of a selective, irreversible Btk inhibitor and its efficacy in an animal model of rheumatoid arthritis is described.
Journal ArticleDOI
CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo.
Joseph J. Buggy,Z. Alexander Cao,Kathryn E. Bass,Erik Verner,Sriram Balasubramanian,Liang Liu,Brian E. Schultz,Peter R. Young,Stacie A. Dalrymple +8 more
TL;DR: Results reveal CRA-024781 to be a novel HDAC inhibitor with potent antitumor activity and an inhibition of tumor cell growth and the induction of apoptosis.
Journal ArticleDOI
Hematopoietic growth factor receptor genes as markers of lineage commitment during in vitro development of hematopoietic cells.
TL;DR: The defined temporal order for the expression of these genes suggests that they may be useful as markers for multiple stages in the development of different hematopoietic cell lineages during embryogenesis.
Journal ArticleDOI
Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase.
David Michael Goldstein,Tom Alfredson,Jay Bertrand,Michelle F. Browner,Ken Clifford,Stacie A. Dalrymple,James Dunn,Jose Freire-Moar,Seth Harris,Sharada S. Labadie,Joann La Fargue,Jean Marc Lapierre,Susan Larrabee,Fujun Li,Eva Papp,Daniel Mcweeney,Chakk Ramesha,Rick Roberts,David Rotstein,Bong San Pablo,Eric B. Sjogren,On-Yee So,Francisco X. Mountain View Talamas,Will Tao,Alejandra Trejo,Armando Villasenor,Mary Welch,Welch Teresa Rosanne,Paul Weller,Phyllis E. Whiteley,Kelly Young,Sheila Zipfel +31 more
TL;DR: In this article, the synthesis and optimization of a series of 5-amino-Nphenyl-1H-pyrazol-4-yl-3-phenylmethanones is described.
Journal ArticleDOI
CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo
Z. Alexander Cao,Kathryn E. Bass,Sriram Balasubramanian,Liang Liu,Brian E. Schultz,Erik Verner,YuQin Dai,Rafael A. Molina,Jack R. Davis,Shawn Misialek,Martin Sendzik,Christine Orr,Ling Leung,Ondine Callan,Peter R. Young,Stacie A. Dalrymple,Joseph J. Buggy +16 more
TL;DR: Results reveal CRA-026440 to be a novel HDAC inhibitor with potent antitumor activity and when used in combination with Avastin, achieved greater preclinical efficacy in HCT 116 colorectal tumor model.